Activity by pscotti
JACKSONVILLE, Fla. – Mayo Clinic’s Florida campus today announced the opening of the Robert and Monica Jacoby Center for Breast Health, which was funded by a $5 million gift from Robert E. and Monica Jacoby of Ponte Vedra, Florida. The new 16,000-square-foot multidisciplinary breast center offers patients a comprehensive array of diagnostic, treatment and after-care services for all types of breast disease, including breast cancer, in a single location.
“As a state-designated Cancer Center of Excellence, Mayo Clinic continues to expand and enhance comprehensive cancer care services to make them available to more patients in Jacksonville as well as all of Florida and the Southeast,” says Gianrico Farrugia, M.D., CEO, Mayo Clinic in Florida. “The Jacoby Center for Breast Health will have a positive impact on patients seeking high quality breast health care. We greatly appreciate the generous gift from the Jacoby family that has made the new breast health center possible on our Florida campus.”
Robert and Monica Jacoby are long-standing patients and benefactors of Mayo Clinic whose gifts to the institution have exceeded $10 million. In addition to the new breast health center, the cardiology suite in Mayo Clinic hospital is named to recognize their generosity. For more than a decade, the Jacoby’s were members of the Mayo Clinic Leadership Council in Florida, serving as ambassadors and advocates of philanthropy.
Journalists: Sound bites with Dr. Sarah McLaughlin, breast center director, are available in the downloads. B'roll of the new center and other related content is also available in the downloads.
MEDIA CONTACT: Paul Scotti, Mayo Clinic Public Affairs, 507-284-5005, firstname.lastname@example.org
As the parents of four daughters, the Jacobys are dedicated to fighting breast cancer. “We want people to know there’s hope,” says Mrs. Jacoby. “From our own experience, we’re convinced Mayo Clinic is the best place to deliver that hope.”
Located on the second floor of the Davis Building on the Mayo Clinic campus at 4500 San Pablo Road, the new breast center features a clinical and support staff of approximately 50 people. They include women’s breast health specialists, breast oncology surgeons, plastic surgeons, breast radiologists, breast medical oncologists, breast radiation oncologists, genetic counselors, breast mammography technicians, nurse navigators and nurses.
Locating all breast sub-specialties in one common area enables specialty consultants to be more readily available to discuss complex cases and meet with patients to explain the sequence of their care. It also allows for a more effective means of scheduling patients, reducing wait times for appointments. The new breast health center provides patients with a serene environment where only patients with similar disorders are evaluated. The full integration of clinical services and research also improves patient access to the latest Mayo Clinic breast-related clinical trials.
“The Jacoby Center for Breast Health is the most comprehensive, multidisciplinary breast health facility in Northeast Florida,” says Sarah McLaughlin, M.D., a Mayo Clinic breast surgeon and director of the new breast center. “It allows for true integration and efficiency of care, as patients can now access breast health experts from virtually every related medical discipline in one location, from genetic testing, breast imaging and diagnosis to oncology care, surgery, plastic surgery and after-care support.”
Mayo Clinic‘s cancer program initiatives include a recently announced collaboration with St. Vincent’s Healthcare to provide expanded Mayo Clinic cancer care services to residents of Northeast Florida. Mayo Clinic also continues its nine-year relationship with the 26.2 with Donna Marathon, which helps fund breast cancer genomics research at Mayo Clinic’s Florida campus.
The Mayo Clinic Cancer Center is the only comprehensive cancer center in Northeast Florida designated by the National Cancer Institute and 1 of only 2 in the state. Mayo Clinic also is 1 of only 4 institutions in Florida designated by the state as a Cancer Center of Excellence and is nationally ranked in cancer in the U.S. News & World Report annual survey of more than 5,000 hospitals.
For more information, call the new Jacoby Center for Breast Health at 904-953-0707.
# # # #
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, the Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 1-855-776-0015 (toll-free).
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit mayoclinic.org or newsnetwork.mayoclinic.org.
JACKSONVILLE, Fla. – Mayo Clinic and the University of North Florida (UNF) are honoring National Breast Cancer Awareness Month in October by hosting the 11th annual “Upbeat Pink: A Musical Tribute to Breast Cancer Survivorship” concert on Friday, Oct. 9 at 7:30 p.m. in Lazzara Performance Hall, UNF Fine Arts Building on the university’s campus in Jacksonville. The Upbeat Pink concert is free and open to the public.
Guest speakers will include Stephanie Hines, M.D. from Mayo Clinic’s Florida campus and Patricia Dunbar-Norris, a breast cancer survivor.
MEDIA CONTACT: Paul Scotti, Mayo Clinic Public Affairs, 507-284-5005, email@example.com [...]
CHICAGO — Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial.
Led by Mayo Clinic, researchers found that ibrutinib and chemotherapy (bendamustine and rituximab, known as BR) reduced the risk of death or cancer progression by almost 80 percent in patients with previously treated CLL or SLL, compared to use of BR alone.
Joe Dangor (on-site at ASCO), Mayo Clinic Public Affairs, 651-261-9089 (cell), firstname.lastname@example.org.
Paul Scotti, Mayo Clinic Public Affairs, 904-953-0199 (office), email@example.com.
JACKSONVILLE, Fla. — Mayo Clinic’s Florida campus has been recognized by the American Nurses Credentialing Center (ANCC) with a Magnet Recognition Program® designation. This credential recognizes health care organizations for quality patient care, nursing excellence and innovations in professional nursing practice. Mayo Clinic is one of only 20 hospitals in Florida and 401 nationally with Magnet Recognition Program status.
In the nursing profession, Magnet recognition is considered the gold seal that epitomizes the importance of quality, safety and improvement; intradisciplinary and interdisciplinary teamwork; understanding of evidence based practice and research; and formal nursing education. It requires organizations to develop, disseminate and enculturate evidenced-based criteria that results in a positive work environment for nurses and, by extension, all employees. U.S. News & World Report includes the Magnet designation as a primary competence indicator in its assessment of almost 5,000 hospitals to rank and report the best medical centers in 16 specialties.
JACKSONVILLE, Fla. — Patients with liver cancer can be cured with a liver transplant. But because of the shortage of donated organs, these patients often die waiting for a liver. That’s because most transplant centers predominantly use livers from donors who die from brain death.
But in the largest study of its kind, transplant physicians at Mayo Clinic in Florida have found that liver cancer patients have the same beneficial outcomes using organs donated by patients who died of cardiac death. The study was recently published online in the American Journal of Transplantation.
MEDIA CONTACT: Paul Scotti, Mayo Clinic Public Affairs, 904-953-0199, firstname.lastname@example.org
JACKSONVILLE, Fla. — A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker — the quantity of tumor-infiltrating lymphocytes (S-TILs) in a biopsy — appears irrelevant when trastuzumab is used.
JACKSONVILLE, Fla., Nov. 9, 2014 — All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.
Now, at the American Association for the Study of Liver Diseases (The Liver Meeting® 2014) in Boston, researchers at Mayo Clinic report that use of two new oral medications post-transplant is safe and beneficial, and requires only 12 weeks of treatment.
“This is the first study to examine the use of these two new drugs — simeprevir and sofosbuvir — in liver transplant recipients, and, based on this large study, we find it to be a better option than current treatment,” says the study’s lead researcher, Surakit Pungpapong, M.D., a transplant hepatologist and an associate professor of medicine at Mayo Clinic in Florida.
Journalists: Soundbites with Dr. Pungpapong are available in the downloads.
Years After Treatment for HER2-Positive Early Stage Breast Cancer Trastuzumab Shows Life-Altering Benefit
JACKSONVILLE, Fla. — After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab (Herceptin) to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.
They found that the use of trastuzumab produced a 37 percent improvement in survival and a 40 percent reduction in risk of cancer occurrence, compared to patients treated with chemotherapy alone.
These findings, published in the Journal of Clinical Oncology, demonstrate how important trastuzumab has been to the treatment of this form of breast cancer, says the study’s lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. [...]
JACKSONVILLE, Flórida 30 de setembro de 2014 — Análises em mais de 8 mil mulheres, que participaram do maior estudo mundial de dois medicamentos para o câncer de mama HER2-positivo, reforçam outras descobertas de estudos clínicos mostrando que o trastuzumabe (Herceptin) deve permanecer como o padrão de tratamento desse tipo de câncer, diz uma pesquisadora da Clínica Mayo. [...]
JACKSONVILLE, Florida, 30 de septiembre 2014 — Investigaciones en más de 8.000 mujeres, que participaron en el estudio más grande del mundo de dos tratamientos para el cáncer de mama HER2-positivo, refuerzan otros hallazgos de este ensayo clínico que demuestran que el fármaco trastuzumab (Herceptin) debiera seguir siendo el tratamiento estándar en este tipo de cáncer, expresa una investigadora de la Clínica Mayo. [...]
JACKSONVILLE, Fla., Sept. 29, 2014 — Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher.
JACKSONVILLE, Fla., Sept. 12, 2014 — The liver transplant team at Mayo Clinic in Florida has found, based on 12 years of experience, that more than half of patients receiving a new liver can be “fast-tracked” to return to a surgical ward room following their transplant, bypassing a one- or two-day stay in the Intensive Care Unit (ICU).
In the September issue of the American Journal of Transplantation, the physicians and researchers have turned their knowledge of who can be safely fast-tracked into a scoring system that other transplant centers can also use — thus sparing patients potentially overly aggressive treatment and saving substantial health care dollars.
JACKSONVILLE, Fla., Sept. 2, 2014 – Mayo Clinic and the University of North Florida are honoring National Breast Cancer Awareness Month in October by hosting the tenth annual “Upbeat Pink: A Musical Tribute to Breast Cancer Survivorship” concert on Friday, Oct. 10 at 7:30 p.m. in Lazzara Performance Hall, UNF Fine Arts Building on the university’s campus in Jacksonville. The Upbeat Pink concert is free and open to the public.
The theme for this year’s program, “Dancing with the Survivors,” showcases a variety of dance music performed by the UNF Wind Symphony, conducted by Gordon Brock, D.M.A., and features special guest artist and multi-instrumentalist, Bill Prince, D.M.A.
Guest speakers will include Laura Vallow, M.D., radiation oncologist at Mayo Clinic and Dianne Wagner, a local breast cancer survivor.
CHICAGO — No maior estudo clínico já realizado para analisar a eficácia do tratamento do câncer de mama HER2 positivo, com um ou com a combinação de dois medicamentos, os pesquisadores relataram que o uso do lapatinibe (Tykerb) não apresentou benefício ao tratamento auxiliar padrão com trastuzumabe (Herceptin), conforme apresentado durante o 50º encontro anual da Sociedade Americana de Oncologia Clínica (ASCO — American Society of Clinical Oncology).
Resultados do estudo clínico de fase III ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study) demonstraram que ao acrescentar lapatinibe ao tratamento com trastuzimabe e quimioterapia não melhorou os resultados gerais para os pacientes (definidos como sobrevida livre da doença ou sobrevida total) e que o uso de lapatinibe aumentou de forma significativa a toxicidade do tratamento. [...]
CHICAGO — En el mayor estudio clínico que prueba la eficacia de un tratamiento versus dos drogas para tratar el cáncer de mama HER2-positivo, lapatinib (Tykerb ) no agregó beneficio en relación a la terapia adyuvante estándar, trastuzumab (Herceptin), según informan investigadores de la 50a reunión anual de la Sociedad Americana de Oncología Clínica (ASCO).
Los resultados del ensayo clínico de fase III, ALTTO (Estudio de Optimización de Tratamiento Adyuvante Lapatinib y/o Trastuzumab), demostraron que agregando lapatinib a trastuzumab y quimioterapia no mejoró el resultado del paciente (definido como supervivencia libre de enfermedad o supervivencia sin progresión de ésta), y que el uso de lapatinib incrementó significativamente la toxicidad del tratamiento. [...]
CHICAGO — Ao examinar porque alguns pacientes com melanoma avançado respondem tão bem à imunoterapia experimental MK-3475, enquanto outros obtêm uma resposta mais fraca, pesquisadores da Clínica Mayo de Jacksonville, na Flórida, descobriram que o tamanho dos tumores, antes do tratamento, era a variável mais forte. [...]
CHICAGO —Al examinar por qué algunos pacientes con melanoma avanzado responden tan bien a la inmunoterapia experimental MK-3475, mientras que otros tienen una respuesta menos sólida, los investigadores de la Clínica Mayo en Jacksonville, Flórida, descubrieron que el tamaño de los tumores, antes del tratamiento, era la variable más importante. [...]
Journalists: Broadcast soundbites with Dr. Perez are available in the downloads.
CHICAGO — In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report at the 50th annual meeting of the American Society of Clinical Oncology (ASCO).
Results of the phase III clinical trial, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization study), demonstrated that adding lapatinib to trastuzumab and chemotherapy did not improve patient outcome (defined as disease-free survival or overall survival), and that use of lapatinib significantly increased toxicity.
“These findings suggest that standard adjuvant (post-surgery) treatment for early stage HER2-positive breast cancer should remain trastuzumab in combination with chemotherapy,” says Edith A. Perez, M.D., deputy director at large of the Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida.
CHICAGO — In examining why some advanced melanoma patients respond so well to the experimental immunotherapy MK-3475, while others have a less robust response, researchers at Mayo Clinic in Florida found that the size of tumors before treatment was the strongest variable.
They say their findings, being presented June 2 at the 50th annual meeting of the American Society of Clinical Oncology (ASCO), offered several clinical insights that could lead to different treatment strategies and perhaps influence staging of advanced melanoma.
“This was the first robust assessment to determine the impact of baseline tumor size on clinical endpoints in patients with metastatic melanoma — in particular — those receiving MK-3475. Our findings suggest the location of spread is less important than the amount of tumor that is present before treatment,” says the study’s lead investigator, Richard W. Joseph, M.D., an oncologist at Mayo Clinic in Florida.
Journalists: Broadcast sound bites with Dr. Joseph are available in the downloads.
JACKSONVILLE, Fla. — Feb. 3 — Uggie, the scene-stealing Jack Russell terrier in the 2012 Oscar-winning film “The Artist” will visit Mayo Clinic on Thursday, Feb. 6. Uggie will be in Jacksonville to meet Mayo’s Caring Canines, the volunteer dogs who greet patients and visitors at the clinic.
The visit by Uggie and his owner/trainer, Omar Von Muller, is open to the public, at 12:30 p.m. Thursday in Walker Auditorium in the clinic’s Davis Building. Von Muller will share Uggie’s amazing success story of going from a puppy headed for the pound to worldwide fame. Uggie will perform some of the tricks that delighted fans of “The Artist” in which he portrayed a loyal dog who courageously rescues his owner from a fire. The film received five Oscars, including Best Picture, Best Director and Best Actor, Jean Dujardin.
There are 19 volunteer dogs in Mayo’s Caring Canines program. They make daily “meet-and-greet” visits to patients and visitors, providing warmth and unconditional love.
“The Caring Canines play a valuable role in supporting Mayo Clinic’s commitment to the healing of mind, body and spirit,” says Peter Dorsher, M.D., chair of Mayo’s Department of Physical Medicine and Rehabilitation. “Uggie’s impact on people worldwide is further evidence of the human/animal bond and how it can improve our health and well-being. We’re delighted to have him meet our volunteer dogs.” [...]